Recent discovery and development of non-peptide vasopressin V₂ receptor agonists

Bibliography

• ALTURA BM, ALTURA BT: Vascular smooth muscle and neurohypophyseal hormones. Fed. Proc. (1977) 36:1853–1860.
   PubMedGoogle Scholar
• HOWL J, ISMAIL T, STRAIN AJ, KIRK CJ, ANDERSON D, WHEATLEY M: Characterization of human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function. Biochem. (1991) 276(Pt 1):189–195.
   Google Scholar
• ••Characterisation of vasopressin receptors.
   Google Scholar
• JARD S, LOMBARD C, MARIE J, DEVILLIERS G: Vasopressin receptors from cultured mesangial cells resemble Via type. Am. J. Physiol (1987) 253(1 Pt 2):F41–F49.
   Google Scholar
• •Characterisation of the Via receptor.
   Google Scholar
• PENIT J, FAURE M, JARD S: Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am. J. Physic] (1983) 244:E72–E82.
   Google Scholar
• THIBONNIER M, ROBERTS JM: Characterization of human platelet vasopressin receptors. J. Gin. Invest. (1985) 76:1857–1864.
   PubMed Web of Science ®Google Scholar
• •Characterisation of the Via receptor.
   Google Scholar
• DORSA DM, MAJUMDAR LA, PETRACCA FM, BASKIN DG, CORNETT LE: Characterization and localization of 3H-arginine8-vasopressin binding to rat kidney and brain tissue, Peptides (1983) 4:699–706.
   Google Scholar
• •Characterisation of the V2 receptor.
   Google Scholar
• BROOKS DP, KOSTER PF, ALBRIGHTSON-WINSLOW CR, STASSEN FL, HUFFMAN WF, KINTER LB: SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatto). J. Pharmacol Exp. Ther. (1988) 245(1):211–215.
   PubMedGoogle Scholar
• CALD WELL N, BRICKSON B, KINTER LB et al.: SK&F 105494: A potent antidiuretic hormone antagonist devoid of partial agonist activity in dogs. J. Pharmacol Exp. Ther. (1988) 247(3):897–901.
   PubMedGoogle Scholar
• BROOKS DP, KOSTER PF, ALBRIGHTSON CR et al.: Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements. Eur. Pharmacol (1989) 160:159–162.
   PubMed Web of Science ®Google Scholar
• ••Peptide antagonist.
   Google Scholar
• RUFFOLO RR JR, BROOKS DP HUFFMAN WE POSTE G: From vasopressin antagonist to agonist: a saga of surprise. Drug News Perspect. (1991) 4(4):217–222.
   Google Scholar
• ••Species differences in peptide antagonists.
   Google Scholar
• YAMAMURA Y, OGAWA H, CHIHARA T et al: OPC-21268, an orally effective, non-peptide vasopressin Vi receptor antagonist. Science (1991) 252:572–574.
   PubMed Web of Science ®Google Scholar
• ••The first non-peptide Via receptor antagonist.
   Google Scholar
• OGAWA H, YAMAMURA Y, MIYAMOTO H et al.: Orally-active, non-peptide vasopressin Vi antagonists. A novel series of 1-(1-substituted 4-piperidyl) -3, 4-dihydro-2-quinolinone.Med. Chem. (1993) 36:2011–2017.
   Google Scholar
• ••SAR of non-peptide Via receptor antagonist.
   Google Scholar
• KONDO K, OGAWA H, NAKAYA K, TOMINAGA M, YABUUCHI Y: Structure-activity relationships of non-peptide vasopressin Via antagonists: 1-(1-multi-substituted benzoyl 4-piperidy1)-3,4-dihydro-2(11-4-quinolinones. Chem. Pharm. Bull (1996) 44(4):725–733.
   PubMedGoogle Scholar
• •SAR of non-peptide Via receptor antagonist.
   Google Scholar
• PETTIBONE DJ, KISHEL MT, WOYDEN CJ et al.: Radiofigand binding studies reveal marked species differences in the vasopressin Vi receptor of rat, rhesus and human tissues. Life Sci. (1992) 50(25):1953–1958.
   PubMedGoogle Scholar
• ••Species difference of non-peptide Viareceptor antagonist.
   Google Scholar
• SERRADEIL-LE GAL C, WAGNON J, LACOUR C et al: Pharmacological profile of SR 49059, a potent non-peptide antagonist of vasopressin receptors. In: Vasopressin. Gross P, Richter D, Robertson GL (Eds), John Libbey Eurotext (1993):529–537.
   Google Scholar
• •Non-peptide Via receptor antagonist.
   Google Scholar
• SERRADEIL-LE GAL C, WAGNON J, GARCIA C et al.: Biochemical and pharmacological properties of SR 49059, a new, potent, non-peptide antagonist of rat and human vasopressin Via receptors. J. Clin. Invest. (1993) 92(1):224–231.
   PubMed Web of Science ®Google Scholar
• SERRADEIL-LE GAL C, RAUFASTE D, MARTY E et al: Binding of [3H] SR 49059, a potent non-peptide vasopressin Via antagonist, to rat and human liver membranes. Biochem. Biophys. Res. Commun. (1994) 199(1):353–360.
   PubMedGoogle Scholar
• TAHARA A, TSUKADA J, ISHII N et al.: Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences. Regal. Pept. (1999) 84(1-3):13–19.
   PubMedGoogle Scholar
• WILLIAMS PD, CLINESCHMIDT BV, ERB JIVI et al.: 1-(1-[4-[(N-acety1-4-piperidinyl)oxy]-2-methoxybenzoyllpiperidin-4-y1)-4113,1-benzoxazin-2(11-4-one (L- 371,257): anew, orally bioavailable, non-peptide oxytocin antagonist. I Med. Chem. (1995) 38:4634–4636.
   PubMed Web of Science ®Google Scholar
• •Non-peptide OT receptor antagonist.
   Google Scholar
• KUO MS, BOCK MG, FREIDINGER RIVI et al: non-peptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridiyOethyl ether terminus. Bioorg. Med. Chem. Lett. (1998) 8:3081–3086.
   PubMed Web of Science ®Google Scholar
• BELL IM, ERB JM, FREIDINGERRM et al.: Development of orally-active oxytocin antagonists: studies on 1 (1 {4 [1 (2 methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyllpiperidin 4 yl) 1,4-dihydrobenzral[1,3]oxazin-2-one (L-372,662) and related pyridines. I Med. Chem. (1998) 41:2146–2163.
   PubMed Web of Science ®Google Scholar
• WILLIAMS PD, BOCK MG, EVANS BE et al.: non-peptide oxytocin antagonists: analogs of L-371,257 with improved potency. Bioorg. Med. Chem. Lett. (1999) 9:1311–1316.
   PubMed Web of Science ®Google Scholar
• WYATT PG, ALLEN MJ, CHILCOTT J et al: Identification of potent and selective oxytocin antagonists. Part 1: Indole and benzofuran derivatives. Bioorg. Med. Chem. Lett. (2002) (In Press).
   Google Scholar
• YAMAMURA Y, OGAWA H, YAMASHITA H et al: Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, non-peptide vasopressin V2 receptor antagonist. Br. Pharmacol (1992) 105:787–791.
   PubMed Web of Science ®Google Scholar
• ••First non-peptide V2 receptor antagonist.
   Google Scholar
• OHNISHI A, ORITA Y, OKAHARA R et al.: Potent aquaretic agent. A novel non-peptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. (1993) 92(6):2653–2659.
   Google Scholar
• ••Clinical study of OPC-31260.
   Google Scholar
• OKADA H, SUZUKI H, KANNO Y, YAMAMURA Y, SARUTA T: Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Gin. ScL (fond) (1994) 86(4):399–404.
   PubMedGoogle Scholar
• NAITOH M, SUZUKI H, MURAKAMI M et al.: Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Jim. .1 Physiol (1994) 267(6 Pt 2):H2245–H2254.
   Google Scholar
• OHNISHI A, ORITA Y, TAKAGI N et al:Aquaretic effect of a potent, orally-active, non-peptide V2 antagonist in men. I Pharmacol Exp. The,: (1995) 272(2):546–551.
   PubMed Web of Science ®Google Scholar
• OGAWA H, YAMASHITA H, KONDO K et al.: Orally-active, non-peptide vasopressin V2 receptor antagonists: a novel series of 144-(benzoylamino)benzoy11-2,3,4,5-tetrahydro-1H-benzazepines and related compounds. Med. Chem. (1996) 39:3547-3555. SAR of non-peptide V2 receptor antagonist.
   Google Scholar
• YAMAMURA Y, NAKAMURA S, ITOH S et al.: OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. Pharmacol Exp. Ther. (1998) 287(3):860–867.
   PubMed Web of Science ®Google Scholar
• ••First report using human V2 receptortransfected cells.
   Google Scholar
• KONDO K, OGAWA H, YAMASHITA H et al.: 7-Chloro-5-hydroxy 1 [2 methy1-4-(2-methylbenzoyl-amino)benzoyl 1-2,3,4,5-tetrahydro- 1H- 1 - benzazepine (OPC-41061): a potent, orally-active non-peptide arginine vasopressin V2 receptor antagonist. Bioorg. Med. Chem. (1999) 8:1743–1754.
   Google Scholar
• ••SAR of non-peptide V2 receptor antagonist.
   Google Scholar
• HIRANO T, YAMAMURA Y, NAKAMURA S, ONOGAWA T, MORI T: Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.' Pharmacol Exp. The,: (2000) 292(1):288–294.
   Google Scholar
• SERRADEIL-LE GAL C, LACOUR C, VALETTE G et al: Characterization of SR 121463 A, a highly potent and selective, orally-active vasopressin V2 receptor antagonist. Clin. Invest. (1996) 98(12):2729–2738.
   Google Scholar
• •Non-peptide V2 receptor antagonist.
   Google Scholar
• VENKATESAN H, DAVIS MC, ALTAS Y, SNYDER JP, LIOTTA DC: Total synthesis of SR 121463 A, a highly potent and selective vasopressin V2 receptor antagonist. Org. Chem. (2001) 66 (11):3653–3661.
   PubMedGoogle Scholar
• SERRADEIL-LE GAL C: An overview of SR 121463, a selective non-peptide vasopressin V2 receptor antagonist. Cardiovasc Drug Rev (2001) 19(3):201–214.
   PubMedGoogle Scholar
• MATSUHISA A, TANAKA A, KIKUCHI K, SHIMADA Y, YATSU T, YANAGISAWA I: non-peptide arginine vasopressin antagonists for both ViA and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'- [(2,3,4,5-tetrahydro- 1H-1 - benzazepin-1 -y1) carbonyl] benzanifide derivatives. Chem. Pharm. Bull. (Tokyo) (1997) 45 (11):1870–1874.
   PubMedGoogle Scholar
• MATSUHISA A, KOSHIO H, SAKAMOTO K, TANIGUCHI N, YATSU Y, TANAKA A: non-peptide arginine vasopressin antagonists for both VIA and V2 receptors: synthesis and pharmacological properties of 2-pheny1-4'-(2,3,4,5-tetrahydro- 1H-1,5-benzodiazepine-1-carbonyl) benzanifide derivatives. Chem. Pharm. Bull. (Tokyo) (1998) 46(101566–1579.
   Google Scholar
• MATSUHISA A, KIKUCHI K, SAKAMOTO K, YATSU T, TANAKA A: non-peptide arginine vasopressin antagonists for both ViA and V2 receptors: synthesis and pharmacological properties of 4'- [5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyll benzanifide and 4'-[S-(substituted methyl)- 2,3Dihydro-1H-1-benzoazepine-1- carbonyllbenzanifide derivatives. Chem. Pharm. Bull. (Tokyo) (1999) 47 (3):329–339.
   PubMedGoogle Scholar
• MATSUHISA A,TANIGUCHE N, KOSHIO H, YATSU T, TANAKA A: non-peptide arginine vasopressin antagonists for both ViA and V2 receptors: synthesis and pharmacological properties of 441,4,5,6-tetrahydroimidazo[4,5-d] [1]benzoazepine-6-carbonyl) benzanifide derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilide derivatives. Chem. Pharm. Bull. (Tokyo) (2000) 48(1):21–31.
   PubMedGoogle Scholar
• SHIMADA Y, TANIGUCHI N, MATSUHISA A, SAKAMOTO K, YATSU T, TANAKA A: Highly potent and orally-active non-peptide arginine vasopressin antagonists for both ViA and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-11-1-1-benzoazepin-1-tetrahydro-11-1-1-benzoazepin-1-yl)carbony11-2-phenylbenzanifide derivatives. Chem. Pharm. Bull. (Tokyo) (2000) 48(11):1644–1651.
   PubMedGoogle Scholar
• ALBRIGHT JD, REICH ME DELOS SANTOS EG et al.: 5-Fluoro-2-methyl-N- [4- (5H-pyrrolo [2, 1[1, 4] benzodiazepin-10(111-4-ylcarbonyl)-3- chlorophenyll benzamide (VPA-985): an orally-active arginine vasopressin antagonist with selectivity for V2 receptors. I Med. Chem. (1998) 41(14):2442–2444.
   Google Scholar
• ALBRIGHT JD, DELOS SANTOS EG, DUSZA JP et al: The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroy1-2,4,5,6-tetrahydropyrazolo [3,4-d]thieno [3,2-blazepines. Bioorg. Med. Chem. Lett. (2000) 10(8):695–698.
   PubMedGoogle Scholar
• OHTAKE Y, NAITO A, HASEGAWA H et al.: Novel vasopressin V2 receptor-selective antagonists, pyrrolo [2, 1 - a] quinoxafine and pyrrolo [2,1-c] [1,4] benzodiazepine derivatives. Bioorg. Med. Chem. (1999) 7(6):1247–1254.
   PubMedGoogle Scholar
• OHKAWA T, ZENKOH T, TOMITA M et al.: Synthesis and characterization of orally-active non-peptide vasopressin V2 receptor antagonists. Chem. Pharm. Bull. (Tokyo) (1999) 47(4):501–510.
   PubMedGoogle Scholar
• FREIDINGER RM, PETTIBONE DJ: Small molecule ligands for oxytocin and vasopressin receptors. Med. Res. Rev (1997) 17(1):1–16.
   PubMedGoogle Scholar
• PETTIBONE DJ, FREIDINGER PM: Discovery and development of non-peptide antagonists of peptide hormone receptors. Biochem. Soc. Trans. (1997) 25(3):1051–1057.
   PubMedGoogle Scholar
• •Review of non-peptide antagonists.
   Google Scholar
• ALBRIGHT D, CHAN PS: Recent advances in the discovery and development of vasopressin antagonists: peptide and non-peptide V1 and V2 receptor antagonists. Corr. Pharm. Design. (1997) 3:615–632.
   Web of Science ®Google Scholar
• •Review of non-peptide AVP receptor antagonists.
   Google Scholar
• FREIDINGER PM: non-peptide ligands for peptide and protein receptors. Corr. Opin. Chem. Biol. (1999) 3 (4):395–406.
   PubMedGoogle Scholar
• •Review of non-peptide antagonists.
   Google Scholar
• TRYBULSKI EJ: Vasopressin receptor modulators: from non-peptide antagonists to agonists. In: Annual Reports in Medicinal Chemistry Doherty (Ed.), Academic Press, (2001) 36:159–168.
   Google Scholar
• •Review of non-peptide AVP receptor antagonists and agonists.
   Google Scholar
• THIBONNIER M, AUZAN C, MADHUM Z, WILKINS P, BERTI-MATTERA L, CLAUSER E: Molecular cloning, sequencing and functional expression of a cDNA encoding the human V1 vasopressin receptor. J. Biol. Chem. (1994) 269(5):3304–3310.
   PubMed Web of Science ®Google Scholar
• ••Cloning of human Via receptor.
   Google Scholar
• HIRASAWA A, SHIBATA K, KOTOSAI K, TSUJIMOTO G: Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem. Biophys. Res. Commons. (1994) 203:72–79.
   PubMedGoogle Scholar
• ••Cloning of human Via receptor.
   Google Scholar
• BIRNBAUMER M, SEIBOLD A, GILERT S et al.: Molecular cloning of the receptor for human antidiuretic hormone. Nature (1992) 357:333–335.
   PubMed Web of Science ®Google Scholar
• ••Cloning of human V2 receptor.
   Google Scholar
• SUGIMOTO T, SAITO M, MOCHIZUKI S, WATANABE Y, HASHIMOTO S, KAWASHIMA H: Molecular cloning and functional expression of cDNA encoding the human Vib vasopressin receptor. " Biol. Chem. (1994) 269:27088-27092. Cloning of human Vib receptor.
   Google Scholar
• KIMURA T, TANIZAWA O, MORI K, BROWNSTEIN MJ, OKAYAMA H: Structure and expression of a human oxytocin receptor. Nature (1992) 356:536–529.
   Google Scholar
• ••Cloning of human OT receptor.
   Google Scholar
• MOUILLAC B, CHINI B, BALESTRE M et al.: Identification of agonist binding sites of vasopressin and oxytocin receptors. Adv. Exp. Med. Biol. (1995) 395:301–310.
   PubMedGoogle Scholar
• PETER J, BURBACH H, ADAN RA et al: Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell. Ma Neurobiol (1995) 15:575–595.
   Google Scholar
• THIBONNIER M, COLES p, CONARTY DM, PLESNICHER CL, SHOHAM M: A molecular model of agonist and non-peptide antagonist binding to the human V1 vascular vasopressin receptor.' Pharmacol Exp. Ther. (2000) 294:195–203.
   PubMed Web of Science ®Google Scholar
• ••Modelling of human Via receptor.
   Google Scholar
• CHINI B, MOUILLAC B, ALA Y et al.: Tyr115 is the key residue for determining agonist selectivity in the V1vasopressin receptor. EMBO J. (1995) 14:2176–2182.
   PubMed Web of Science ®Google Scholar
• KONDO K, OGAWA H, SHINOHARA T et al.: Novel design of non-peptide AVP V2 receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoy1)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template. J. Med. Chem. (2000) 43(23):4388–4397.
   PubMedGoogle Scholar
• ••SAR of non-peptide V2 receptor agonists.
   Google Scholar
• NAKAMURA S, YAMAMURA Y, ITOH S et al.: Characterization of a novel non-peptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes. Br. J. Pharmacol (2000) 129:1700–1706.
   PubMedGoogle Scholar
• •Characterisation of non-peptide V2 receptor agonist.
   Google Scholar
• NAKAMURA S, HIRANO T, TSUJIMAE K et al.: Antidiuretic effects of a non-peptide vasopressin V2-receptor agonist, OPC-51803, administered orally to rats. J. Pharmacol Exp. The]: (2000) 295(3):1005–1011.
   PubMedGoogle Scholar
• •Characterisation of a non-peptide V2 receptor agonist.
   Google Scholar
• CHAN PS, PARK CH, LAI FM et al.: VNA-932, a non-peptide orally-active and selective vasopressin V2 receptor agonist, produces potent antidiuretic effects in conscious rats, dogs and monkeys. World Congress on neurohypophysial Hormones. Edinburgh, UK (1999). 5UN39.
   Google Scholar
• •Characterisation of a non-peptide V2 receptor agonist.
   Google Scholar
• ASHWELL MA, BAGLI JF, CAGGIANO TJ et al.: Synthesis and structure-activity relationships (SAR) of pyrrolobenzodiazepines related to the potent selective orally-active non-peptide vasopressin V2-receptor agonist VNA-932. 219th ACS Meeting. San Francisco, USA (2000). MEDI202.
   Google Scholar
• DUSZA JP, CAGGIANO TJ, ASHWELL MA et al.: VNA-932: first orally-active, non-peptide, vasopressin V2 receptor selective agonist. 219th ACS Meeting. San Francisco, USA (2000) MEDI203.
   Google Scholar